

Analysis for Covid-19 Vaccinations Policies at MENA Region

Abdalla Abotaleb*

WHO Project Manager, President of Global Society of Biologicals and Outcomes Research (GLSBOR), Spain

***Corresponding Author:** Abdalla Abotaleb, WHO Project Manager, President of Global Society of Biologicals and Outcomes Research (GLSBOR), Spain.

Received: October 13, 2021; **Published:** November 25, 2021

Abstract

Objectives

- Identify elements influencing effectiveness of vaccinations policies.
- Overcoming vaccinations challenges.
- Analyze impact of effective vaccinations policies on health system.
- Analyze impact of effective vaccinations policies on countries economy.

Method: Data collated from various sources - published scientific studies, preprint material, agency reports, media communication, public surveys, etc. - with specific focus on the approach itself, Covid-19 trends, healthcare system response, policy and measures overview, and implications.

Results: The following results were founded.

Conclusion and Recommendations:

- Sustainable and dynamic vaccination policies play major rules on facing pandemic pressures on health systems.
- Efficient purchasing policies had positive impact on economic resources for health systems.
- Diversity of awareness policies important for succeeding of vaccinations plans.

Keywords: Policy Analysis; COVID -19 Vaccination Policies

Objectives of the Study

- Identify elements influencing effectiveness of vaccinations policies.
- Overcoming vaccinations challenges.
- Analyze impact of effective vaccinations policies on health system.
- Analyze impact of effective vaccinations policies on countries economy.




Figure 1



Figure 2

Method

Data collated from various sources - published scientific studies, preprint material, agency reports, media communication, public surveys, etc. - with specific focus on the approach itself, Covid-19 trends, healthcare system response, policy and measures overview, and implications.

HEALTHCARE VALUE CHAIN		EXPECTED IMPACT FROM COVID-19	FUTURE IMPACT	POINT OF IMPACT/POLICY
Pharma/MedTech R&D		<ul style="list-style-type: none"> Stronger support is expected for innovation in medicine, vaccine, bio-tech, MedTech & IIOT Temporarily slower pace of R&D affected by tightened medical resource and constraint on patient enrollment 		<ul style="list-style-type: none"> Short Term: R&D affected Mid/Long Term: stronger support for innovation
Manufacturing		<ul style="list-style-type: none"> The SARS epidemic only brought 3-6 months of phased growth for pharma manufacturing therefore a short-term demand is expected post Covid-19 outbreak for antiviral drugs (esp. OTC), medical hygiene & disinfection materials, IVD etc. 		Rising demand for some drugs while drop in others may counteract each other
Distribution	Pharmaceutical Distributor	<ul style="list-style-type: none"> The logistics of medicine & consumables will further concentrate, with better information regarding consumables Distributors will continue augmenting service levels e.g. strengthening pharmaceutical services 		Government expected to continue building a unified & functioning emergency supplies
	Pharmacy on- & off-line	<ul style="list-style-type: none"> Short-term increase of sales expected for over the counter and traditional Chinese medicine cold/antiviral drugs due to stockpiling & attempts to prevent Covid-19 infection; Longer term service enhancements expected e.g. electronic prescription, hospital prescription outflow 		Facilitated by the "Prescription Outflow" policy, large chained pharmacy will expand & concentrate
	Internet Health Platform	<ul style="list-style-type: none"> Quick launch & scale-up of e-commerce pharmacy, online diagnosis, epidemic tracking and psychological counseling Better e-commerce integration expected between pharma, logistics and hospitals for online diagnosis 		E-commerce platform's richness in category, SKU, and warehousing & logistics will expedite its growth
Healthcare	Hospital	<ul style="list-style-type: none"> Due to the outbreak, volume of out and in-patients is expected to drop by 50-70% in Q1; hospital income in 2020 may suffer a decline of 25-30% 		<ul style="list-style-type: none"> Acceleration of "Internet+"; more investment in primary healthcare, and infectious disease hospital Growth of ICU constrained by lack of qualified staff
	Physical Examination Center	<ul style="list-style-type: none"> Volume of physical examinations dropped by 60-70% in Q1 General trend of higher health awareness will keep the market growing at +15% p.a. in 2021 and next 3 years 		Physical examination penetration & frequency will steadily increase with higher health awareness
	ICL	<ul style="list-style-type: none"> In 2020, a huge increase in COVID-19 nucleate & CT testing has been experienced, while other tests suffered from a drop in demand; optimistic outlook for the market is purported by investment in primary healthcare 		Limited impact
Patient/Payer	Social Health Insurance	<ul style="list-style-type: none"> In Feb 2020 NHSA pushed for nationwide implementation of a digital insurance card Since establishment of NHSA, health insurance fund has been kept steadily, unified UEBMI⁽²⁾ could cover 23 months 		Since Feb. 2020, corporate payment to UEBMI could be reduced by half, a max. relief of 150 Bn RMB
	Private insurance	<ul style="list-style-type: none"> Pressure on certain health insurance funds demonstrates the importance of diversified sources of medical payment Complementary effect of private insurance in this epidemic is recognized, and its coverage will be encouraged 		Feb. 3, CBIRC supported insurance providers to include COVID-19 in accident/illness insurance coverage
	Self-Paying	<ul style="list-style-type: none"> Up until 2018, personal health expenditure as a % of the total was at 28.6%; Beijing c. 16%, Shanghai c. 20% The Government is expected to continuously push for slowly lowering the share of personal health expenditure 		"Healthy China 2030" mandated to lower personal health expenditure (1% total) to c. 25%

Figure 3: Impact of COVID -19 on innovation in health care, delivery of primary health care and digital health.




Figure 4: Long-term policy will likely encourage healthcare innovations.

Results

The following results were founded.




Figure 5: Impact of capacity enhancement on vaccinations policies.




Figure 6: Impact of system Capacity enhancement & Efficiency of Vaccination plans.




Figure 7: How can awareness strategies affect on plans effectiveness.




Figure 8: Purchasing impact.




Figure 9: Economy and vaccines.




Figure 10: System capacity & how can affect vaccines polices.

Conclusion and Recommendations

- Sustainable and dynamic vaccination policies play major rules on facing pandemic pressures on health systems.
- Efficient purchasing policies had positive impact on economic resources for health systems.
- Diversity of awareness policies important for succeeding of vaccinations plans [1-11].

Bibliography

1. Coronavirus Disease (COVID-19) - events as they happen (2019).
2. The Lancet Public Health COVID-19 puts societies to the test. Lancet Public Health 5.5 (2020): e235.
3. Ferguson N., et al. "Re- port 9: impact of non-pharmaceutical interventions (NPIs) to reduce COVID19 mortality and healthcare demand Imperial College London (2020).

4. Giesecke J. "The invisible pandemic". *The Lancet* (2020).
5. Infection prevention and control during health care when coronavirus disease (COVID-19) (2020).
6. <https://covid19partnersplatform.who.int/>
7. Infection prevention and control for the safe management of a dead body in the context of COVID-19 (2020).
8. Srivastava A., *et al.* "Treatment Guidelines Working Group on Behalf of The World Federation of Hemophilia. Guidelines for the management of hemophilia". *Haemophilia* 19 (2013): e1-47.
9. Drelich DA. Hemophilia A. Medscape (2019).
10. Rocino A., *et al.* "Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy". *Blood Transfusion* 12 (2014): 575-598.
11. Colvin BT., *et al.* "Inter Disciplinary Working Group. European principles of haemophilia care". *Haemophilia* 14 (2008): 361-374.

Volume 4 Issue 12 November 2021

©All rights reserved by Abdalla Abotaleb.